Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Net Income towards Common Stockholders: 2020-2024

Historic Net Income towards Common Stockholders for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to -$54.8 million.

  • Xeris Biopharma Holdings' Net Income towards Common Stockholders rose 103.95% to $621,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 75.22%. This contributed to the annual value of -$54.8 million for FY2024, which is 11.92% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Net Income towards Common Stockholders of -$54.8 million as of FY2024, which was up 11.92% from -$62.3 million recorded in FY2023.
  • Xeris Biopharma Holdings' Net Income towards Common Stockholders' 5-year high stood at -$54.8 million during FY2024, with a 5-year trough of -$122.7 million in FY2021.
  • For the 3-year period, Xeris Biopharma Holdings' Net Income towards Common Stockholders averaged around -$70.6 million, with its median value being -$62.3 million (2023).
  • Per our database at Business Quant, Xeris Biopharma Holdings' Net Income towards Common Stockholders slumped by 34.66% in 2021 and then soared by 34.23% in 2023.
  • Yearly analysis of 5 years shows Xeris Biopharma Holdings' Net Income towards Common Stockholders stood at -$91.1 million in 2020, then plummeted by 34.66% to -$122.7 million in 2021, then rose by 22.87% to -$94.7 million in 2022, then soared by 34.23% to -$62.3 million in 2023, then grew by 11.92% to -$54.8 million in 2024.